title: Lupus nephritis: treatment of resistant disease.
abstract: Lupus nephritis (LN) remains a major cause of ESRD and is associated with a >4-fold increase in mortality and significant morbidity in patients with lupus. The treatment of LN has evolved significantly over the past decade due to data from well conducted randomized controlled trials. We are currently in an era in which effective regimens exist in the form of induction and maintenance agents. Histopathologic classification of LN remains one of the main factors guiding therapy.
authors.affiliation: Division of Nephrology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
authors.forename: Sean
authors.initials: S
authors.lastname: Kalloo
authors.forename: Nidhi
authors.initials: N
authors.lastname: Aggarwal
authors.forename: Prince
authors.initials: P
authors.lastname: Mohan
authors.forename: Jai
authors.initials: J
authors.lastname: Radhakrishnan
mesh_terms: D004351:Drug Resistance; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000401:mortality*; D009017:Morbidity; D016032:Randomized Controlled Trials as Topic
chemical_list: D007166:Immunosuppressive Agents